Kashyap Patel, MD, immediate past president of Community Oncology Alliance (COA) and CEO of Carolina Blood and Cancer Care Associates, talks about bringing together different stakeholders in the oncology space in order to benefit patients and providers.
Kashyap Patel, MD, gives a preview of what Community Oncology Alliance (COA) will be focusing on at the 2023 Community Oncology Conference.
Transcript
What are you looking forward to at the 2023 Community Oncology Conference?
This year's COA meeting is going to focus on multiple issues of public interest, beginning from what's happening in the 340B space, what COA is doing in a congressional effort to address the PBMs (pharmacy benefit managers). Because we all understand that the US health care space is quite complicated, with multiple factors beginning from the state, the local, the commercial payer, the Medicare Advantage plans, the MCO (Multi-Criteria Optimization). So all of this makes the space very complicated, and combine that with 340B and health care equity issues.
COA's effort is to try to bring the stakeholders from multiple areas—from the payer space to the provider space to the pharma space—to bring almost like a coalition of like-minded people together that combines the science, the ethics, morality, public policy, and the steps that COA has been taking to ensure that we remain constantly engaged and share information, of COA's bold and widespread effort, beginning from Congress to state level, to ensure that we extend the cause which is advocating for committee oncology policies and patients. We remain united in our efforts to be spokespersons for patients and the providers. In the same token, we also take the leap of ensuring that access to care—which is provided at multiple practices in a smaller rural area, where if we disappear, there will be no access—stays as what it is.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More